Annual Drug Patent Expirations for FETZIMA
Fetzima is a drug marketed by Allergan and is included in one NDA. It is available from one supplier. There are three patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for FETZIMA.
This drug has forty-eight patent family members in twenty-seven countries.
The generic ingredient in FETZIMA is levomilnacipran hydrochloride. One supplier is listed for this compound. Additional details are available on the levomilnacipran hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com